Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimab

Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11.

Presentations in partnership with Regeneron include studies evaluating dupilumab in patients with bullous pemphigoid, atopic dermatitis (AD), chronic spontaneous urticaria, and prurigo nodularis. New analyses evaluating Sanofi’s pipeline medicine amlitelimab, an anti-OX40-ligand monoclonal antibody, will also be presented, including long-term (52-week) results from the STREAM-AD phase 2b study in adult patients with moderate-to-severe AD, and the first interim results from the RIVER-AD phase 2 study in adult patients who did not initially achieve clinical response in Part 1 of the STREAM-AD study at 24 weeks.
“Our breadth of data at AAD demonstrates our commitment to patients and advancing treatments for an unmatched number of type 2 inflammatory skin conditions driven by intense itch,” Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology and Oncology Development, said in a press release. “The Dupixent data being shared reinforce its clinical evidence across skin diseases, including results from a phase 2/3 study in patients with bullous pemphigoid. Additionally, we are excited to share new data highlighting the potential of our novel anti-OX40-ligand, amlitelimab, in atopic dermatitis, which offers a unique mechanism of action that could help normalize the overactive immune system and restore immune balance without T-cell depletion.”